|
Discontinuations for adverse events in >1% women randomized to duloxetine. Values are expressed as n (%). |
|||
| Duloxetine |
Placebo |
P |
|
|
|
|||
| (N = 60) |
(N = 61) |
||
|
|
|||
| For any adverse event |
16 (26.7) |
4 (6.6) |
.003 |
| Dizziness |
4 (6.7) |
2 (3.3) |
.439 |
| Nausea |
2 (3.3) |
0 (0.0) |
.244 |
| Somnolence |
2 (3.3) |
0 (0.0) |
.244 |
| Asthenia |
1 (1.7) |
0 (0.0) |
.496 |
| Flatulence |
1 (1.7) |
0 (0.0) |
.496 |
| Hypertension |
1 (1.7) |
0 (0.0) |
.496 |
| Insomnia |
1 (1.7) |
0 (0.0) |
.496 |
| Palpitations |
1 (1.7) |
0 (0.0) |
.496 |
| Phobia |
1 (1.7) |
0 (0.0) |
.496 |
| Urinary hesitation |
1 (1.7) |
0 (0.0) |
.496 |
| Vomiting |
1 (1.7) |
0 (0.0) |
.496 |
Lin et al. BMC Urology 2008 8:2 doi:10.1186/1471-2490-8-2 |
|||